The supplied filings link Guangzhou Aimooe Technology Co., Ltd. to one 510(k) record, K262214, decided Substantially Equivalent (SESE) on 15 October 2026. The submission was received 30 June 2026, reviewed under the Traditional pathway, not by a third party, and assigned product code HAW with a Neurology review panel. The applicant name on the FDA record matches the company name used on its own published pages, which describe optical tracking and electromagnetic navigation components. [1][2][5]
The documented FDA clearance
K262214 covers Disposable Reflective Marker Spheres under the model designations AM-BK115S and AM-BL130S. The FDA record lists the applicant as Guangzhou Aimooe Technology Co., Ltd., with a Guangzhou city and postal code 510700 on the filing address, a contact named Peifeng Guan, and a Summary as the statement or summary type. The decision description reads Substantially Equivalent, and the FDA database page records the same received and decision dates, Traditional type, Neurology panel and no third-party review. [1][2]
The FDA's final-decisions listing for 15 October 2026 includes K262214 with the same device name and applicant, placing the clearance among other substantially equivalent decisions published that day. The supplied portfolio snapshot contains one linked record, a 510(k), with a decision count of one SESE; the sample of that collection is the same single record, also SESE. These counts describe the supplied filings as of the snapshot and are not measures of company sales, total portfolio or safety performance. [4][1]
What the company publishes about its products
Aimooe's own site describes optical tracking and electromagnetic navigation solutions, naming an electromagnetic tracking system in the MAGPILOT series and a product catalogue covering optical positioning cameras, electromagnetic positioning systems, tracking markers, tracking tools and an Aimooe workstation. The same publisher lists solution areas for neurosurgical navigation, robotic-assisted TMS treatment and robotic-assisted knee replacement, alongside MagPilot tracking supply and optical tracking camera pages. [3][8]
A product page for snap-on passive retro-reflective markers describes a single-use, sterile 11.5 mm passive marker sphere compatible with OEM instruments that have snap-fit mounting posts, positioned for wireless tracking and robotic-assisted thoracic surgery. A separate FAQ page states that reflective marker spheres under the AimMarker name support factory-ready EO sterilization and that products requiring sterilization should follow standard protocols and individual manuals. These are company-published descriptions, not FDA findings in the supplied record. [6][7]
Company identity and stated background
The company's about page states that Guangzhou Aimooe Technology Co., Ltd. was founded in 2017 and describes itself as a high-tech company integrating research, development, manufacture and sales around optical tracking technology for the medical industry. The same page lists 100 or more patents and copyrights, 19 years of optical technology experience, 100 or more scientific research papers, 120 employees and 50% of the workforce in research and development, and states that Aimooe provides core components of surgical robots. Those figures are the publisher's own claims. [5]
The site footer gives a contact address at 30-6 Kaitai Road, Huangpu District, Guangzhou, 510700, China, matching the postal code on the FDA filing. The FDA record's address field is a filing address and is not treated here as a verified headquarters. No parent company, brand ownership or corporate group relationship is established by the public documents; the FDA legal applicant is the named entity, and brand names such as AimMarker and MagPilot appear only as company-published product names. [5][1][7]
How the record should be read
The clearance covers disposable reflective marker spheres, a tracking accessory, while the company's published catalogue extends to cameras, electromagnetic systems, tools and workstations. The public documents do not show FDA clearance for those other items, and the single linked record should not be read as covering the wider catalogue. The filing's Neurology panel and HAW product code describe regulatory classification of the cleared device, not clinical performance. [1][2][8]
Details absent from the public documents remain unknown, including manufacturing sites tied to the clearance, distribution arrangements, customers, pricing and any certifications beyond the FDA decision. The 510(k) summary referenced in the record was not provided in the source text, so its contents, including any testing or comparison device, are not described here. [1][2]

